ÂÜÀòÂÒÂ×

Scott Platshon is an experienced investor currently affiliated with EcoR1 Capital, LLC, a biotech-focused investment advisory firm, since October 2015. In addition to this role, Scott serves as a Board Observer for BridgeBio Oncology Therapeutics and Zymeworks Inc., and as a Board Member for Terremoto Biosciences, Ajax Therapeutics, and Kumquat Biosciences Inc. Scott also held the position of Chief Operating Officer at Panacea Acquisition Corporation I & II from July 2020 to May 2023. Previous board observer roles include PellePharm and Ashvattha Therapeutics, and a brief tenure at Janux Therapeutics. Scott holds a Bachelor of Science degree in Bioengineering and Biomedical Engineering from Stanford University, graduating in 2014, and attended Menlo School from 2005 to 2009.